Get AI intraday signals

GET DAILY SIGNALS

EMR(+7.76%) vs WYNN(+6.84%): Detailed Comparison for Beginner Swing Traders

EMR in downward trend: price may drop because broke its higher Bollinger Band on January 21, 2025

EMR broke above its upper Bollinger Band on January 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In of the 42 cases the stock fell afterwards. This puts the odds of success at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for EMR moved out of overbought territory on January 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EMR entered a downward trend on January 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 17, 2025. You may want to consider a long position or call options on EMR as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EMR just turned positive on January 17, 2025. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

EMR moved above its 50-day moving average on January 21, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EMR crossed bullishly above the 50-day moving average on January 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.140) is normal, around the industry mean (4.594). P/E Ratio (33.296) is within average values for comparable stocks, (51.569). Projected Growth (PEG Ratio) (3.046) is also within normal values, averaging (2.219). Dividend Yield (0.018) settles around the average of (0.022) among similar stocks. P/S Ratio (4.097) is also within normal values, averaging (9.670).